🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

842 results for “Eli” Clear

  1. SELINEXOR, Selinexor placebo for 20 mg tablets is formulated for oral administration. selinexor placebo tablets are film coated bi-convex round tablets

    Karyopharm Therapeutics

    endometrial cancer

    phase 3 small molecule active

    1 trial

  2. SELPERCATINIB, CARBOPLATIN , SELPERCATINIB, PEMBROLIZUMAB, CISPLATIN , PEMETREXED

    Eli Lilly Co.

    Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. SPD422 (anagrelide hydrochloride)

    Takeda Pharmaceuticals International AG

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial

  4. Sabin Strain Inactivated Poliovirus Vaccine

    SINOVAC BIOTECH LTD

    Poliomyelitis

    phase 3 mab completed

    1 trial

  5. Satralizumab, Satralizumab

    Roche Registration Limited

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

    phase 3 small molecule active

    1 trial

  6. Selinexor

    Karyopharm Therapeutics

    Endometrial Cancer

    phase 3 small molecule active

    2 trials

  7. Selinexor

    Karyopharm Therapeutics

    Dedifferentiated Liposarcoma

    phase 3 small molecule completed

    1 trial

  8. Selinexor

    Karyopharm Therapeutics

    Myelofibrosis

    phase 3 small molecule active

    2 trials

  9. Selinexor

    Karyopharm Therapeutics

    Multiple Myeloma

    phase 3 small molecule active

    12 trials

  10. Selinexor (combination therapy)

    Karyopharm Therapeutics

    Relapsed/Refractory Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  11. Soliris 300 mg concentrate for solution for infusion, Pozelimab, Cemdisiran, Ultomiris 300 mg/3 mL concentrate for solution for infusion

    Pharma Mar S.A.

    Paroxysmal nocturnal haemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  12. Soquelitinib

    Corvus Pharmaceuticals

    Peripheral T-Cell Lymphoma, Not Otherwise Specified

    phase 3 small molecule active

    1 trial

  13. Standard of Care

    Telix Innovations

    Metastatic Prostate Cancer

    phase 3 small molecule terminated

    1 trial

  14. Subcutaneous Tislelizumab

    Beone Medicines Ireland Limited

    Metastatic Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial

  15. Suprefact Depot 9,45 mg implantat, Pamorelin 11,25 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Pamorelin 22,5 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Pamorelin 3,75 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Eligard 45 mg poeder en oplosmiddel voor oplossing voor injectie, LEUPRORELIN ACETATE, CAMCEVI 42 mg prolonged-release suspension for injection, Gonapeptyl Depot 3,75 mg poeder en oplosmiddel

    Disc Medicine

    low-volume metastatic castration-sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  16. TAK-771

    Takeda Pharmaceuticals International AG

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  17. TAK-881

    Takeda Pharmaceuticals International AG

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    phase 3 mab active

    1 trial

  18. TAK-881, HyQvia 100 mg/mL solution for infusion for subcutaneous use, HyQvia 100 mg/mL solution for infusion for subcutaneous use

    Takeda Pharmaceuticals International AG

    Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  19. TAMOXIFEN , EXEMESTANE , ANASTROZOLE , LETROZOLE , Verzenios 50 mg film-coated tablets

    Eli Lilly Co.

    Breast Cancer

    phase 3 small molecule active

    1 trial

  20. TAMOXIFEN, LETROZOLE, ANASTROZOLE, FULVESTRANT, LEUPRORELIN, OXYBUTYNIN, GOSERELIN, VENLAFAXINE, LEUPRORELIN, GOSERELIN, EXEMESTANE, VENLAFAXINE

    Rein Therapeutics

    Breast cancer

    phase 3 small molecule active

    1 trial

  21. TARA-002

    Protara Therapeutics

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 3 small molecule active

    1 trial

  22. TIRZEPATIDE, TIRZEPATIDE, Retatrutide, Retatrutide, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, Retatrutide, Retatrutide, TIRZEPATIDE, Placebo to match LY, Retatrutide, Placebo to match LY

    Eli Lilly Co.

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 small molecule active

    1 trial

  23. TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, Placebo to match LY3298176, TIRZEPATIDE, TIRZEPATIDE

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  24. TLX-101-Tx + Lomustine

    Telix Innovations

    Neoplastic Disease

    phase 3 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources